Latest Related Content

Wednesday, January 04, 2012

Genetic Variants Affecting Clopidogrel Metabolism Have Minor Influence on Platelet Reactivity After Elective Percutaneous Coronary Intervention

By András Komócsi, Orsolya Rideg, Gyöngyvér Költö, András Vorobcsuk, Daniel Aradi
Wednesday, January 04, 2012

Paraoxonase-1 (PON1) Activity And PON1 Polymorphisms Have No Effect On Platelet Reactivity In Patients Treated With Clopidogrel

By Jean-Pierre P. Dery, Abdelouahed Khalil, Ugo Déry, Mélanie Roy, Pierluigi Tricoci, Richard Becker, Stéphane Rinfret, Éric Larose, Gérald Barbeau, Robert DeLarochellière, Josep Rodés-Cabau, Olivier F. Bertrand
Wednesday, January 04, 2012

<b>Pharmacodynamic Effect of Double-dose Clopidogrel versus Adding Dipyridamole In Patients With High On-treatment Platelet Reactivity (ACCEL-DIP) study</b>

By Yongwhi Park, Young-Hoon Jeong, Jeong-Rang Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang
Wednesday, January 04, 2012

CYP3A4 Genetic Status May Be Associated with Increased Vulnerability to the Adverse Effect of Calcium Channel Blockers on Clopidogrel Response Variability

By Jin Joo Park, Kyung Woo Park, Jeehoon Kang, Ki-Hyun Jeon, Si-Hyuk Kang, Hyo Suk Ahn, Han-Mo Yang, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Byung-Hee Oh, Young-Bae Park, Hyo-Soo Kim
Wednesday, January 04, 2012

Stopping Clopidogrel 1 year After Drug-Eluting Stent (DES) Implantation: Is It Safe?

By Nalyaka Sambu, Hazel Dent, Timothy Warner, Nicola Englyst, Philip Leadbeater, Alex Hobson, Alison Calver, Simon Corbett, Huon Gray, Iain Simpson, John Morgan, Nick Curzen
Wednesday, January 04, 2012

Genetic Determinants of Clopidogrel Responsiveness in Koreans

By Jin Joo Park, Kyung Woo Park, Jeehoon Kang, Ki-Hyun Jeon, Si-Hyuk Kang, Hyo Suk Ahn, Han-Mo Yang, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Byung-Hee Oh, Young-Bae Park, Hyo-Soo Kim
Wednesday, January 04, 2012

”Safety of Dual Antiplatelet Therapy in Patients Treated with Coronary Drug Eluting Stents.”

By Andrzej Drewnicki, Maciej Lesiak, Malgorzata Pyda, Marek Grygier, Wlodzimierz Skorupski, Aleksander Araszkiewicz, Przemyslaw Mitkowski, Stefan Grajek
Wednesday, January 04, 2012

Methods of measurement of aspirin-mediated antiplatelet. Degree of correlation and agreement between two “point of care: VerifyNow®Aspirin assay and PFA-100®

By Jose Maria Cubero Gomez, Maria Asunción Navarro Puerto, Maria Isabel De Mier Barragan, Francisco J. Sanchez-Burguillos, Pastor L. Perez-Santigosa, Francisco J. Molano Casimiro, Luis F. Pastor Torres
Wednesday, January 04, 2012

Inhibition of Platelet Aggregation by Prostaglandin E1 (PGE1) May Be Attenuated in Diabetic Patients During Therapy with Clopidogrel

By Rolf P. Kreutz, Perry Nystrom, Yvonne Kreutz, Jiao Miao, Richard Kovacs, David Flockhart, Zeruesenay Desta, Yan Jin
Wednesday, January 04, 2012

Ticagrelor Enhances Adenosine-induced Coronary Vasodilatory Responses in Humans—a Randomised, Double-Blind, Placebo-Controlled, Crossover, Single Centre Study Using...

By Li-Ming Gan, Ann Wittfeldt, Håkan Emanuelsson, Sven Nylander, Magnus Andersson
Wednesday, January 04, 2012

Response to Prasugrel in ST Elevation Myocardial Infarction Patients: is it as Rapid as we Expected?

By Frédéric Casassus, Lionel Leroux, Chloe James, Sali Sidibe, Agnalys Desplantes, David Naibo, Benjamin Seguy, Pierre Chevallereau, Pierre Coste
Wednesday, January 04, 2012

Clinical Outcomes Of Intracoronary Eptifibatide Bolus-only versus Intracoronary Bolus and Intravenous Infusion of Eptifibatide in Primary Percutaneous Coronary Intervention

By Dinna K. Soon, Hee Hwa Ho, Kwok Kong Loh, Yau Wei Ooi, David Foo, Paul Ong, Fahim Jafary
Wednesday, January 04, 2012

Protease Activated Receptor-1 (PAR-1) Mediated Platelet Aggregation is Dependant on Clopidogrel Response

By Rolf P. Kreutz, David A. Flockhart, Yvonne Kreutz, Jeffrey A. Breall
Wednesday, January 04, 2012

Adherence to Evidence-Based Medical Therapy According to Management Strategy in Patients With Acute Coronary Syndrome.

By Samer Mansour, Riahi Mounir, Louis-Mathieu Stevens, Nicolas Noiseux, Andre Kokis, Francois Gobeil
Wednesday, January 04, 2012

Safety and Efficacy for the Use of Prasugrel in Patients Undergoing Percutaneous Coronary Intervention and Anticoagulated with Bivalirudin.

By Ana Laynez, Rebecca Torguson, Camille Hauville, Gabriel Sardi, Itsik Ben-Dor, Gabriel Maluenda, Michael A. Gaglia, Manuel A. Gonzalez, Israel M. Barbash, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman
Wednesday, January 04, 2012

Long-Term Dual Anti-Platelet Therapy in Patients Treated with Bare Metal Stent Implantation: Results From the NHLBI Dynamic Registry

By Gopi Manthripragada, Oscar C. Marroquin, Helen Vlachos, Sameer Khandhar, Catalin Toma, Joon S. Lee, David O. Williams, Kevin E. Kip, Suresh Mulukutla
Wednesday, January 04, 2012

The Association Between Duration of Clopidogrel Therapy After Saphenous Vein Graft Intervention And Long-Term Death And Myocardial Infarction

By Amit Sachdeva, Sumati Bavisetty, Gerald Beckham, Vicken Aharonian, Prakash Mansukhani, Gregg W. Stone, Naing Moore, Ric Hyett, Richard Contreras, Somjot S. Brar
Wednesday, January 04, 2012

Evaluation of Dose Requirements for Prolonged Bivalirudin Administration in Patients with Renal Insufficiency and Suspected Heparin-Induced Thrombocytopenia.

By James W. Wisler, Jeffrey B. Washam, Richard C. Becker
Wednesday, January 04, 2012

In hospital and 30 day outcomes in all-comer percutaneous coronary intervention with bivalirudin: Initial report of the prospective EUROVISION Registry. Hamon M, Nienaber C,...

By Martial Hamon
Wednesday, January 04, 2012

Use of the REG1 Anticoagulation System During PCI May Improve Bleeding and Ischemic Complications Compared with Heparin: A PCI Substudy from the Phase 2B RADAR Trial

By Thomas J. Povsic, John P. Vavalle, Laura H. Aberle, Steven L. Zelenkofske, Roxana Mehran, Mauricio G. Cohen, Christopher E. Buller, Jan H. Cornel, Jaroslaw D. Kasprzak, Gilles Montalescot, Peter Fail, Ian J. Sarembock, John H. Alexander
Wednesday, January 04, 2012

Efficacy and Safety of Bivalirudin Compared to Unfractionated Heparin in Relation to the Use of “Preclose” Technique Using the Perclose Vascular Closure Device Among Patients...

By Shyam Poludasu, Usman Baber, Chabbra Sandeep, Jennifer Yu, Rebecca Pinnelas, Avery E. Clark, Roxana Mehran, George Dangas, Annapoorna S. Kini, Samin K. Sharma
Wednesday, January 04, 2012

Benefits of CD 34 Antibody Coated Stent in Patients with High Risk for Bleeding During Dual Antiplatelet Therapy.

By Miltiadis Papalexandris, Hubertus Degen, Carsten Stoepel, Thomas Lickfeld, Thorsten Schneider, Carlos Freitas, Michael Haude
Wednesday, January 04, 2012

The impact of paraoxonase-1 activity on the incidence of intra-stent thrombus after drug-eluting stent implantation in the Japanese CYP2C19*2 carriers receiving clopidogrel

By Ryo Nishio, Junya Shite, Toshiro Shinke, Hiromasa Otake, Masayuki Nakagawa, Ryoji Nagoshi, Amane Kozuki, Takumi Inoue, Hirotoshi Hariki, Tsuyoshi Osue, Yu Taniguchi, Masamichi Iwasaki, Noritoshi Hiranuma, Akihide Konishi, Hiroto Kinutani, Yoko Haraguchi, Tatsuro Ishida, Ken-ichi Hirata
Wednesday, January 04, 2012

Comparison of bivalirudin versus heparin during PCI in patients receiving prasugrel M Hamon, S Marso, SV Rao, M Valgimigli, F Verheugt, A Gershlick, Y Wang, GP Steg, E...

By Martial Hamon
Wednesday, January 04, 2012

Outcomes After Revascularization with Everolimus- and Sirolimus Eluting Stents In Patients with Acute Coronary Syndromes. A Substudy of the SORT OUT IV Trial.

By Lisbeth Antonsen, Per Thayssen, Henrik Steen Hansen, Michael Maeng, Hans-Henrik Tilsted, Evald Hoej Christiansen, Knud Noerregaard Hansen, Hans Erik Boetker, Jan Ravkilde, Lars Krusell, Morten Madsen, Henrik Toft Soerensen, Leif Thuesen, Jens Flensted Lassen, Lisette Okkels Jensen